USZ BioResource COVID-19
NCT04414657 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2022-11-14
Summary
Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).
Conditions
- COVID19
Interventions
- OTHER
-
blood sampling for biobank
blood sampling for biobank
Sponsors & Collaborators
-
Regina Grossmann
lead OTHER
Principal Investigators
-
Regina Grossmann, Dr med · Head of Clinical Trials Center University Hospital Zurich
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-09
- Primary Completion
- 2021-09-30
- Completion
- 2021-09-30
Countries
- Switzerland
Study Locations
More Related Trials
-
Mayo Clinic Phage Program Biobank
NCT05314426 ·Status: ENROLLING_BY_INVITATION
-
Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites
NCT05769803 ·Status: UNKNOWN ·Phase: NA
-
Biobank of Samples From Patients With Infectious Diseases
NCT06722131 ·Status: NOT_YET_RECRUITING
-
Long COVID in Military Organisations
NCT04942249 ·Status: UNKNOWN
-
Development of a Swiss Surveillance Database for Molecular Epidemiology of Hypervirulent and Multi-drug Resistant Pathogens
NCT04172025 ·Status: RECRUITING
-
Development and Validation of (Bio)Sensors for the Identification of Pathogens
NCT06548841 ·Status: COMPLETED
-
COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2
NCT04318314 ·Status: UNKNOWN
-
Dräger COVID-19 Antigen Test Clinical Performance Study
NCT04698993 ·Status: TERMINATED ·Phase: NA
-
SARS-CoV-2 Infection in COVID-19 Vaccinated Patients
NCT05060939 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™
NCT02221232 ·Status: TERMINATED ·Phase: PHASE2
-
Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research
NCT01089153 ·Status: COMPLETED
-
Immune Response and Risk of Serious Infection to SARS-Cov2
NCT04410432 ·Status: COMPLETED
-
Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants
NCT04301310 ·Status: WITHDRAWN ·Phase: PHASE1
-
CORE Study COVID-19
NCT04531202 ·Status: UNKNOWN
-
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
NCT00666276 ·Status: COMPLETED
-
Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
NCT04610515 ·Status: COMPLETED
-
Nasal Swab Study to Explore the Nasal Microbia
NCT02535442 ·Status: COMPLETED
-
Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)
NCT04365322 ·Status: UNKNOWN
-
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031 ·Status: NOT_YET_RECRUITING
-
Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.
NCT04488484 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Efficacy and Safety of Nano-S1
NCT05822180 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effect of Systematic Screening of Residents and Caregivers With Covid-19 by Nasopharyngeal Swab (RT-PCR)
NCT05085522 ·Status: UNKNOWN
-
TOcilizumab and Covid-19 : Risk of Severe INfection
NCT05017441 ·Status: UNKNOWN
-
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
NCT05256316 ·Status: COMPLETED
-
Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.
NCT04345315 ·Status: UNKNOWN